BIOHAVEN PHARMACEUTICAL HOLDING CO LTD
NYSE: BHVN (Biohaven Ltd.)
Last update: 1 hour ago11.36
-0.14 (-1.22%)
| Previous Close | 11.50 |
| Open | 11.50 |
| Volume | 1,366,644 |
| Avg. Volume (3M) | 3,170,311 |
| Market Cap | 1,507,341,184 |
| Price / Book | 12.19 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stifel Financial Corp | 31 Dec 2025 | 9,939,856 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 5,620,271 |
| Bellevue Group Ag | 30 Sep 2025 | 2,802,853 |
| Infinitum Asset Management, Llc | 30 Sep 2025 | 1,700,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (RBC Capital, 93.66%) | Buy |
| Median | 15.50 (36.44%) | |
| Low | 11.00 (HC Wainwright & Co., -3.17%) | Hold |
| 11.00 (UBS, -3.17%) | Hold | |
| Average | 16.00 (40.85%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 10.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 21 Jan 2026 | 22.00 (93.66%) | Buy | 12.87 |
| Morgan Stanley | 06 Jan 2026 | 21.00 (84.86%) | Buy | 9.62 |
| 18 Nov 2025 | 26.00 (128.87%) | Buy | 9.45 | |
| HC Wainwright & Co. | 26 Dec 2025 | 11.00 (-3.17%) | Hold | 11.15 |
| 03 Dec 2025 | 11.00 (-3.17%) | Hold | 9.12 | |
| UBS | 26 Nov 2025 | 11.00 (-3.17%) | Hold | 9.48 |
| JP Morgan | 20 Nov 2025 | 15.00 (32.04%) | Buy | 9.63 |
| BTIG | 18 Nov 2025 | 16.00 (40.85%) | Buy | 9.45 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |